Recent clinical trials have explored novel treatments in pSS, encompassing experimental drugs like Lanraplenib (spleen tyrosine kinase inhibitor), Filgoinib (Janus kinase-1 inhibitor), Tirabrutinib (Bruton’s tyrosine kinase inhibitor), CDZ173 (PI3K inhibitor), and Dazodalibep (CD40L antagonist and Tn3 fusion protein) (Mæland et al., 2021). Here, JAK1 is linked to peeling skin syndrome.